Natdac 60mg Daclatasvir Tablet – NS5A Inhibitor for Chronic Hepatitis C

Natdac 60 (Daclatasvir) (generic equivalent to Daklinza) is a prescription direct-acting antiviral (DAA) used to treat Chronic Hepatitis C Virus (HCV) infection. Modern DAA therapies like Natdac 60 deliver cure rates exceeding 95% in most HCV genotypes.
Composition: Daclatasvir (60mg)
Treatment Course: Typically 8–12 weeks.
Manufacturer: Natco Pharma Ltd
Prescription-only antiviral. Use under the supervision of a hepatologist or infectious disease specialist. Baseline genotyping and viral load testing required before starting treatment.